Avience Biomedicals Limited
NSE: AVIENCE · Medical Equipment & Supplies
Share price ₹263.85
up 4.93% · close of 20 Nov 2026
Your ratios
Market cap
₹145 Cr
P/E ratio
16.6
EPS FY to Mar 2026
P/B ratio
Pending
₹30 Cr IPO · by 23 Jun
ROCE
26.9%
ROE
32.3%
Dividend yield
0.0%
as of 20 Nov 2026
1 · Overview
Overview
Price, valuation, sales and profit over the range you pick. Prices as of the last close; results as filed.
At a glance · Max
Every small chart follows the range above. Point at it to read a value; click it to open it.2 · Results
Latest result · Q2 FY27
What the last results showed. Whether management kept its word is in Pro.
Net profit ₹5.54 Cr, up 22.0% on Sep 2025
Years to March, 2023–2026 · key lines
| Line | Mar 2023FY23 | Mar 2024FY24 | Mar 2025FY25 | Mar 2026FY26 |
|---|---|---|---|---|
| Sales₹ crore | 10.92 | 23.83change on a year before +118% | 44.92change on a year before +89% | 52.46change on a year before +17% |
| Expenses₹ crore | 19.65 | 33.40 | 37.36 | |
| Operating profit₹ crore | 4.18 | 11.52change on a year before +176% | 15.10change on a year before +31% | |
| Operating margin% of sales | 17.54% | 25.65% | 28.78% | |
| Other income₹ crore | 0.41 | 0.58 | 0.29 | |
| Interest₹ crore | 0.94 | 1.45 | 1.70 | |
| Depreciation₹ crore | 0.62 | 0.88 | 1.22 | |
| Profit before tax₹ crore | 3.03 | 9.77 | 12.47 | |
| Tax rate% of profit before tax | 28.71% | 27.33% | 29.75% | |
| Net profit₹ crore | 2.16 | 7.10change on a year before +229% | 8.75change on a year before +23% | |
| EPS₹ per share | 5.36 | 17.61change on a year before +229% | 21.71change on a year before +23% |
Small figure: change on the year before. Lines that are 0 or blank in every column are not shown.
The last 4 quarters, Mar 2025 to Sep 2026 · key lines
| Line | Mar 2025Q4 FY25 | Sep 2025Q2 FY26 | Mar 2026Q4 FY26 | Sep 2026Q2 FY27 |
|---|---|---|---|---|
| Sales₹ crore | 24.47 | 26.82 | 25.69change on a year before +5% | 31.13change on a year before +16% |
| Expenses₹ crore | 17.86 | 19.57 | 18.00 | 22.74 |
| Operating profit₹ crore | 6.61 | 7.25 | 7.69change on a year before +16% | 8.39change on a year before +16% |
| Operating margin% of sales | 27.01% | 27.03% | 29.93% | 26.95% |
| Other income₹ crore | 0.46 | 0.06 | 0.23 | 0.52 |
| Interest₹ crore | 0.69 | 0.65 | 0.89 | 0.61 |
| Depreciation₹ crore | 0.48 | 0.56 | 0.66 | 0.79 |
| Profit before tax₹ crore | 5.90 | 6.10 | 6.37 | 7.51 |
| Tax rate% of profit before tax | 27.63% | 25.74% | 33.75% | 26.23% |
| Net profit₹ crore | 4.27 | 4.54 | 4.22change on a year before -1% | 5.54change on a year before +22% |
| EPS₹ per share | 10.59 | 11.26 | 10.47change on a year before -1% | 10.10change on a year before -10% |
Small figure: change on the same quarter a year earlier.
Sales and profit: growth a year, compounded, to Mar 2026; TTM is the last 12 months. Share price: to the latest close. A span can cross a demerger or an acquisition.
Sales
a year, compounded
- 3 years
- 69%
- TTM
- 11%
Return on equity
average over the span
- 3 years
- 38%
- Last year
- 32%
3 · Quality & value
Answers
The questions investors ask most, each answered first in one line, then shown. From the company's own numbers.
How fast it has been growing
Fewer than three years of filings — too early to judge growth.
Whether it grew faster than its sector
It grew 68.7% a year against a sector median of 19.7% — 49.0 percentage points faster.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
It has no steady three-year profit record yet, so growth cannot be weighed against the price.
How it compares with its peers
Against companies the exchange files under the same label (Medical Equipment & Supplies), it ranks 1 of 11 on returns, 1 of 11 on margin.
A longer bar is a better rank.
What makes it hard to beat — and is that still true?
A wide advantage: it earns 26.9% on capital, ahead of 91% of companies filed under the same label.
Whether its growth pays for itself
No — Over the 3 years of cash statements on file it made ₹10 crore of cash from the business but spent ₹26 crore on plant and equipment, ₹16 crore more than it made; the gap was from lenders and shareholders.
Peers here are the 11 companies the exchange files under the same label (Medical Equipment & Supplies). That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Business score & profit checks
How strong the business is, and whether its profit is real cash. Facts only, not advice.
Business score
59 out of 100
How strong the business is, in one number. Last changed 20 Nov 2026.
Profit checks: is the profit real cash?
5 of 7 checks clear
2 of 9 checks could not be run.
Simple checks on the accounts. Which 2 are flagged is in Pro.
Key numbers & peers
Grouped by topic. Each number says what period it is for.
Price
- Market cap
- ₹145 Cr
- Prev close
- ₹263.85
- 52w High
- ₹392
- 52w Low
- ₹225
- Beta
- —
- Price CAGR 1y
- —
- Price CAGR 3y
- —
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Valuation
- P/E ratioEPS FY to Mar 2026
- 16.6
- Industry P/E
- 42.7
- P/B ratio₹30 Cr IPO · by 23 Jun
- Pending
- EV / EBITDA₹30 Cr IPO · by 23 Jun
- Pending
- Enterprise value₹30 Cr IPO · by 23 Jun
- Pending
- PEG ratio
- —
- Dividend yield
- 0.0%
Returns
- ROCE
- 26.9%
- ROCE 5y average
- 27.3%
- ROE
- 32.3%
- ROE 3y average
- 38.0%
- ROE last year
- 32.0%
- Return on assets
- 11.7%
Sales, profit & margins
- Annual revenue
- ₹52.5 Cr
- Annual profit
- ₹8.75 Cr
- EPS
- ₹21.7
- Operating margin
- 28.8%
- Net profit margin
- 16.7%
- EBITDA margin
- 28.8%
- Sales latest quarterSep 2026 quarter
- ₹31.1 Cr
- Profit latest quarterSep 2026 quarter
- ₹5.54 Cr
- OPM latest quarterSep 2026 quarter
- 27.0%
Growth a year
- Sales growth 3y
- 68.7%
- Sales growth 5y
- —
- Sales growth TTM
- 11.0%
- Profit growth 3y
- —
- Profit growth 5y
- —
- Profit growth TTM
- —
- YoY quarterly sales growthSep 2026 vs Sep 2025
- 16.1%
- YoY quarterly profit growthSep 2026 vs Sep 2025
- 22.0%
Balance sheet
- Book Value
- Pending
- Face Value
- ₹10.0
- Borrowings
- ₹28.9 Cr
- Total debt
- ₹27.2 Cr
- Total cash
- ₹5.73 Cr
- Debt / Equity
- 0.4
- Interest coverage
- 8.3
- Reserves / Equity
- 6.8
Cash & payout
- Operating cash flow
- ₹5.91 Cr
- Free cash flow
- -₹7.44 Cr
- FCF yield
- -6.3%
- Net cash flow
- -₹1.95 Cr
- Dividend payout
- 0.0%
Holdings
- Promoter holding
- 64.6%
- FII holding
- 0.0%
- DII holding
- 3.5%
- Public holding
- 31.9%
A newly listed company shows “Pending” until it files a balance sheet after its IPO: the last one is from before the issue, so the IPO money would be counted twice.
Peers
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield | Profit qtr ₹ Cr | Profit change | Sales qtr ₹ Cr | Sales change | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Molbio Diagnostics Limited | 1,495.50 | 111.4 | 17,234 | 0.00% | 7.70 | -92.79% | 259 | -55.36% | 19.31% |
| Poly Medicure Limited | 1,635.70 | 52.5 | 16,580 | 0.21% | 95.1 | +3.40% | 581 | +30.78% | 14.20% |
| Sahajanand Medical Technologies Limited | 527.60 | 81.3 | 5,364 | 0.00% | 26.5 | +26.04% | 373 | +24.89% | 11.42% |
| Tarsons Products Limited | 303.40 | 197.3 | 1,614 | 0.00% | -0.34 | -110.24% | 124 | +20.83% | 4.56% |
| Fischer Medical Ventures Limited | 22.33 | 1,560 | 0.21% | 0.80 | -94.19% | 107 | +24.48% | 11.58% | |
| Laxmi Dental Limited | 187.57 | 27.0 | 1,032 | 0.00% | 10.0 | +11.51% | 79.5 | +10.03% | 15.17% |
| Fabtech Technologies Limited | 140.37 | 20.9 | 624 | 0.44% | 15.0 | -46.34% | 92.1 | -24.20% | 14.00% |
| Avience Biomedicals Limited | 263.85 | 16.6 | 145 | 0.00% | 5.54 | +22.03% | 31.1 | +16.07% | 26.95% |
| Medianof the whole group of 11, 20 Nov 2026 | 43.3 | 0.00% | -31.89% | +17.50% | 13.99% |
Median: the middle value of the whole peer group of 11 companies. Price and rupee sizes are left blank there, as a middle value of those says little.
4 · Balance sheet & cash
Balance sheet
What the company owns and what it owes, at each year end and at the filed half-years. ₹ crore.
At Mar 2026: ₹74.5 cr of assets, and who funds them
Shareholders’ own money funds 42% of it; borrowings 39%.
What it owns
- Fixed assets ₹16.1 cr 22%
- Being built ₹12.9 cr 17%
- Investments ₹0.03 cr 0%
- Everything else ₹45.6 cr 61%
Who funds it
- Shareholders’ money ₹31.4 cr 42%
- Borrowings ₹28.9 cr 39%
- Everything else ₹14.2 cr 19%
Each year end. Newest year end shaded.
| Line, ₹ crore | Mar 2024FY24 | Mar 2025FY25 | Mar 2026FY26 |
|---|---|---|---|
| Equity capital | 3.28 | 4.03 | 4.03 |
| Reserves | 2.94 | 18.63 | 27.38 |
| Borrowings | 15.13 | 22.16 | 28.93 |
| Other liabilities | 13.18 | 11.60 | 14.20 |
| Total funding | 34.53 | 56.42 | 74.54 |
| Fixed assets | 10.25 | 13.10 | 16.06 |
| Being built (CWIP) | 0.03 | 4.62 | 12.85 |
| Investments | 0.03 | 0.03 | 0.03 |
| Other assetsreceivables, cash, rest | 24.22 | 38.67 | 45.60 |
| Total assets | 34.53 | 56.42 | 74.54 |
Cash flows
Real money coming in and going out — from the business, from investments and from loans. ₹ crore.
Pick a period to see where its cash went.
In words
- The business brought in ₹5.91 cr, 39% of its operating profit before tax.
- It put ₹13.3 cr into assets and investments.
- It raised ₹5.42 cr from shareholders and lenders.
- Cash in hand fell by ₹1.95 cr. Free cash flow: −₹7.44 cr.
| Line, ₹ crore | Mar 2024FY24 | Mar 2025FY25 | Mar 2026FY26 |
|---|---|---|---|
| From the business | 1.02 | 3.39 | 5.91 |
| From investing | -3.90 | -9.54 | -13.27 |
| From financingdividends, buybacks, loans | 2.93 | 10.21 | 5.42 |
| Net change in cash | 0.05 | 4.06 | -1.95 |
| Free cash flow | -2.81 | -5.87 | -7.44 |
| Cash ÷ operating profitbefore tax | 24.00% | 29.00% | 39.00% |
Free cash flow = cash from the business − spending on assets + what assets sold fetched; the same rule for years and half-years.
Efficiency ratios
How fast customers pay and how well capital earns. Each year, Mar 2024 to Mar 2026.
Debtor days
146 days
Days customers take to pay. Lower is faster.
146 days in FY26, against 140 days in FY25. Over these 3 years: 124 days (FY24) to 146 days (FY26).
Inventory days
217.5 days
Days stock sits before it is sold.
217.5 days in FY26, against 176.3 days in FY25. Over these 3 years: 176.3 days (FY25) to 290.3 days (FY24).
Days payable
119.9 days
Days it takes to pay its suppliers.
119.9 days in FY26, against 98.1 days in FY25. Over these 3 years: 98.1 days (FY25) to 129.9 days (FY24).
Cash conversion cycle
243.9 days
Debtor days plus inventory days, less days payable.
243.9 days in FY26, against 218.1 days in FY25. Over these 3 years: 218.1 days (FY25) to 284.3 days (FY24).
Working capital days
74.1 days
Days of sales tied up in running the business.
74.1 days in FY26, against 70.3 days in FY25. Over these 3 years: 28.6 days (FY24) to 74.1 days (FY26).
Return on capital (ROCE)
27.0%
Operating profit on the capital used.
27.0% in FY26, against 34.2% in FY25. Over these 2 years: 27.0% (FY26) to 34.2% (FY25).
5 · Owners & payouts
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividend a share, by the year of its ex-date
No dividend on record.
Share of profit paid as dividend
No dividend payout is filed for this company.
Splits, bonuses & buybacks
None on record.
Big trades by funds and insiders
- SURESH ZUNZUNWALAbulk deal, NSEBought 42,000 · at ₹245.3820 Jul 2026
- SURESH ZUNZUNWALAbulk deal, NSESold 42,000 · at ₹265.5520 Jul 2026
- MANSI SHARE AND STOCK BROKING PRIVATE LIMITEDbulk deal, NSEBought 90,000 · at ₹321.203 Jul 2026
- GINNI FINANCE PRIVATE LIMITEDbulk deal, NSEBought 31,800 · at ₹321.213 Jul 2026
- NEO APEX SHARE BROKING SERVICES LLPbulk deal, NSESold 29,400 · at ₹321.483 Jul 2026
- GREEN PEAKS ENTERPRISES LLPbulk deal, NSESold 42,000 · at ₹394.2529 Jun 2026
- NIRAJ RAJNIKANT SHAHbulk deal, NSEBought 98,400 · at ₹395.2025 Jun 2026
- NEO APEX SHARE BROKING SERVICES LLPbulk deal, NSEBought 50,400 · at ₹414.9525 Jun 2026
- GREEN PEAKS ENTERPRISES LLPbulk deal, NSEBought 48,600 · at ₹414.9525 Jun 2026
- KIFS ENTERPRISEbulk deal, NSEBought 30,000 · at ₹395.2025 Jun 2026
6 · Price & trading
Open interestPRO
Where option traders are positioned on this stock.
7 · Business
About
What the company is, from our own records: where it sits, where its revenue comes from, and where it works.
- Sector
- Healthcare
- Industry
- Medical Equipment & Supplies
- Symbol
- AVIENCE
- ISIN
- INE0V9I01017
- Part of
- Nifty SME Emerge
Sites · 2
- Manufacturing Unit 1Noida, Uttar Pradesh
- New manufacturing unit at Plot No. 70, Sector 28, Medical Device Park, YEIDAGautam Buddha Nagar, Uttar Pradesh
Industry numbers
The numbers that matter most in this industry, from the company's own filings and earnings calls. Each one says its period.
Revenue and margin
- EBIT marginSep 2026 quarter24.41%
Profit quality
- Other income shareSep 2026 quarter6.92%
- Interest coverSep 2026 quarter13.31x
Growth
- Revenue growth (YoY)Sep 2026 quarter16.07%
Capex
- CapexFY to Mar 2026₹13.4 Cr
- Capex to revenueFY to Mar 202625.45%
How they have moved
EBIT margin · quarterly
Source: Computed from the filings
| Sep 26 | 24.41% | Computed from the filings |
| Jun 26 | — | not filed |
| Mar 26 | 27.36% | Computed from the filings |
| Dec 25 | — | not filed |
Other income share · quarterly
Source: Computed from the filings
| Sep 26 | 6.92% | Computed from the filings |
| Jun 26 | — | not filed |
| Mar 26 | 3.61% | Computed from the filings |
| Dec 25 | — | not filed |
Interest cover · quarterly
Source: Computed from the filings
| Sep 26 | 13.31x | Computed from the filings |
| Jun 26 | — | not filed |
| Mar 26 | 8.16x | Computed from the filings |
| Dec 25 | — | not filed |
Revenue growth (YoY) · quarterly
Source: Computed from the filings
| Sep 26 | 16.07% | Computed from the filings |
| Jun 26 | — | not filed |
| Mar 26 | 4.99% | Computed from the filings |
Capex (fiscal year) · yearly
Source: Computed from the filings
| FY26 | ₹13.4 Cr | Computed from the filings |
| FY25 | ₹9.26 Cr | Computed from the filings |
| FY24 | ₹3.83 Cr | Computed from the filings |
Capex to revenue (fiscal year) · yearly
Source: Computed from the filings
| FY26 | 25.45% | Computed from the filings |
| FY25 | 20.61% | Computed from the filings |
| FY24 | 16.07% | Computed from the filings |
Supply chain
Links to other companies, as recorded in our map from filings and announcements. A news event that hits one of them can reach Avience Biomedicals Limited through this map.
Buys from · 1
- Mindray Medical India PrivateTrading goods (advanced IVD solutions)
Competes with · 7 companies
- Molbio Diagnostics
- Poly Medicure
- Sahajanand Medical Technologies
- Tarsons Products
- Fischer Medical Ventures
- Laxmi Dental
- Fabtech Technologies
Shaded: the companies compared in Key numbers & peers. Each name opens that company’s page.
8 · News & documents
News and what it reaches
Filings and news about Avience Biomedicals Limited, and bigger events that reach it through its owners, rivals, customers or suppliers. Newest first. Open one to see how the effect spreads.
No recent news or filings for this company.
Documents
Earnings calls, results presentations and annual reports, straight from the company and the exchanges.
No documents on record yet.
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.